Prosecution Insights
Last updated: April 19, 2026
Application No. 18/012,257

COSMETICS

Non-Final OA §103§112
Filed
Dec 22, 2022
Examiner
LIU, TRACY
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shiseido Company Ltd.
OA Round
3 (Non-Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
3y 3m
To Grant
83%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allow Rate
363 granted / 657 resolved
-4.7% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
99 currently pending
Career history
756
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
50.2%
+10.2% vs TC avg
§102
6.3%
-33.7% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 657 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims included in the prosecution are claims 1, 5, 7 and 9-11. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/17/2025 has been entered. Applicants' arguments, filed 11/17/2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 10 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 10 recites wherein the sorbitan sesquiisostearate is in the amount of about 0.25%. The claim fails to comply with the written description requirement since there is no support for this limitation. The specification does not disclose wherein the amount of sorbitan sesquiisostearate may be slightly less than 0.25% or slightly more than 0.25%. The specification discloses wherein sorbitan sesquiisostearate may be exactly 0.25% in Table 1. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 9 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 9 recites the limitation "the at least one coloring pigment" in the first line. There is insufficient antecedent basis for this limitation in the claim. Claim 9 depends from claim 1 and claim 1 does not recite at least one coloring pigment. Therefore, the scope of the at least one coloring pigment in claim 9 is unclear. Response to Arguments The rejection is maintained since claim 1 does not recite at least one coloring pigment. It is unclear whether the at least one coloring pigment is referring to the at least two kinds of pigments in claim 1 or is referring to another pigment in addition to the at least two kinds of pigments. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 1. Claims 1, 5, 7, 9 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Camus et al. (US 2005/0036964, Feb. 17, 2005) (hereinafter Camus) in view of Wei et al. (US 2012/0276031, Nov. 1, 2012) (hereinafter Wei), Blin et al. (US 2005/0106197, May 19, 2005) (hereinafter Blin), and Russ et al. (US 2006/0067960, Mar. 30, 2006) (hereinafter Russ). Camus discloses a composition capable of lightening a dark skin while at the same time giving a natural makeup result (¶ [0007]). The composition is of foundation type comprising, in a physiologically acceptable medium, at least one coloring agent (¶ [0029]). The composition has a lightness L* of between 30 and 40 (¶ [0030]). Measurement of L* is in the CIE 1976 Space (¶ [0081]). The coloring agent(s) may be present in the composition of foundation type in a content ranging from 0.5% to 30% by weight (¶ [0136]). The coloring agents may be treated in order to make them hydrophobic (¶ [0150]). Suitable coloring agents include yellow iron oxide coated with perfluoroalkyl phosphate, titanium oxide treated with alumina, and mixtures thereof (¶ [0154]). The composition of foundation type may be a water-in-oil emulsion (¶ [0295]). The fatty phase may comprise at least one volatile or non-volatile oil or a mixture thereof (¶ [0196]). These volatile or non-volatile oils may be hydrocarbon-based oils, silicone oils, or mixtures thereof (¶ [0199]). Volatile oils that may be used include volatile linear silicone oils (¶ [0201]). The volatile oil may be present in a composition in a content ranging from 0.1% to 98% by weight (¶ [0202]). The non-volatile oils may be present in a composition in a content ranging from 0.01% to 90% by weight (¶ [0213]). The composition of foundation type may also contain emulsifying surfactants present especially in a proportion ranging from 0.1 to 30% by weight (¶ [0226]). These surfactants may be nonionic surfactants (¶ [0227]). The composition may comprise polyvinylpyrrolidones (¶ [0260]). Camus differs from the instant claims insofar as not disclosing wherein the coloring agents have different particle diameters. However, Wei discloses that a cosmetic composition comprising a mixture of metal oxide pigments (e.g., titanium dioxide) of various sizes and shapes may simultaneously provide high coverage on the skin and achieve a natural look characterized by high diffuse transmittance (¶ [0009]). Such a cosmetic may be a foundation (¶ [0012]). Fig. 1 is a schematic representation of the light bending effect of traditional high refractive pigments and a mixture of metal oxide particles of various sizes and shapes (¶ [0014]). Suitable pigments include yellow iron oxide and titanium oxides (¶ [0022]). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art to have formulated the coloring agents of Camus to have different particle diameters motivated by the desire to have the composition simultaneously provide high coverage on the skin and achieve a natural look characterized by high diffuse transmittance as taught by Wei. The combined teachings of Camus and Wei do not teach wherein the composition comprises behenic acid. However, Blin discloses a cosmetic composition for making up skin (abstract). The non-volatile liquid fatty phase of the composition comprises at least one non-silicone non-volatile oil, such as a non-volatile hydrocarbon-based oil (¶ [0250]). Suitable non-silicone non-volatile oils include behenic acid (¶ [0254]). The composition may be in the form of a water-in-oil emulsion (¶ [0287]). Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. Camus discloses wherein the composition comprises non-volatile oils. Accordingly, it would have been obvious to one of ordinary skill in the art to have incorporated behenic acid into the composition of Camus since it is a known and effective non-volatile oil for water-in-oil emulsions as taught by Blin. The combined teachings of Camus, Wei, and Blin do not teach wherein the composition comprises sorbitan sesquiisostearate. However, Russ discloses a cosmetic composition (abstract). The composition may be in the form of an emulsion (¶ [0033]). The composition may comprise surfactants such as sorbitan sesquiisostearate (¶ [0083]). Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. Camus discloses wherein the composition comprises a surfactant. Accordingly, it would have been obvious to one of ordinary skill in the art to have incorporated sorbitan sesquiisostearate into the composition of Camus since it is a known and effective surfactant for cosmetic emulsions as taught by Russ. 2. Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Camus et al. (US 2005/0036964, Feb. 17, 2005) (hereinafter Camus) in view of Wei et al. (US 2012/0276031, Nov. 1, 2012) (hereinafter Wei), Blin et al. (US 2005/0106197, May 19, 2005) (hereinafter Blin), Russ et al. (US 2006/0067960, Mar. 30, 2006) (hereinafter Russ), and further in view of Ogawa et al. (JP 2007223976-A, Sep. 6, 2007) (hereinafter Ogawa). The teachings of Camus, Wei, Blin, and Russ are discussed above. Camus, Wei, Blin, and Russ do not teach wherein the composition has a lightness L* of 24 or less. However, Ogawa discloses a correcting method for covering leukoderma parts of pigmentary skin diseases using color tones within a specific range. The correcting method comprises applying a composition having a color tone with an L* value of ≤ 45, and a* value of ≤ 10, and a b* value of ≤ 25 (abstract). The method corrects a color difference between a healthy skin site and a disease site using a composition having hue and brightness (Technical Feature). The composition contains a coloring material and a coating agent (page 6 of translation, sixth paragraph). Suitable coloring materials include inorganic pigments such as iron oxide and titanium oxide (page 6 of translation, seventh paragraph). Suitable coating agents include polyvinylpyrrlidone (page 6, penultimate paragraph). Accordingly, it would have been prima facie obvious to one of ordinary skill in the art to have modified the composition of Camus to have a lightness L* of ≤ 45 motivated by the desire to correct a color difference between a healthy skin site and a disease site as taught by Ogawa. One of ordinary skill in the art would have modified the composition to have a lightness less than 30 depending on the severity of the color difference. One of ordinary skill in the art would have had a reasonable expectation of success since Ogawa discloses wherein coloring materials and coating agents are needed and Camus discloses these components. Response to Arguments Applicant argues that the claimed invention has surprising and unexpected results as shown in Table 1 of the specification as filed. The Examiner submits that although Applicant’s showing appears to be probative of unexpected results, the independent claim is not commensurate in scope with Applicant’s showing. Instant claim 1 does not recite an amount of sorbitan sesquiisostearate. One of ordinary skill in the art would not reasonably expect all amounts of sorbitan sesquiisostearate to be reasonably representative of 0.25% since according to page 5 of the instant specification, surfactants are included for improving dispersibility and a negligible amount of sorbitan sesquiisostearate would not reasonably improve dispersibility, which would affect color streak. This is shown in Comparative Ex. 1 which does not comprise sorbitan sesquiisostearate and has a color streak grade of D. Moreover, instant claim 1 does not recite wherein the composition comprises a volatile silicone oil and an amount thereof. One of ordinary skill in the art would not reasonably expect the same results as the showing without a volatile silicone oil since unexpected results with absence of syneresis requires oil because one would expect a composition without oil to have an absence of syneresis. Also, the amount of volatile silicone oil should be recited in instant claim 1 since one would reasonably expect a composition with negligible amount of oil to have an absence of syneresis. As such, Applicant’s argument is unpersuasive. Conclusion Claims 1, 5, 7 and 9-11 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRACY LIU whose telephone number is (571)270-5115. The examiner can normally be reached Mon-Fri 9 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TRACY LIU/Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Dec 22, 2022
Application Filed
Apr 11, 2025
Non-Final Rejection — §103, §112
Jul 03, 2025
Response Filed
Jul 14, 2025
Final Rejection — §103, §112
Nov 06, 2025
Examiner Interview Summary
Nov 06, 2025
Applicant Interview (Telephonic)
Nov 17, 2025
Request for Continued Examination
Nov 18, 2025
Response after Non-Final Action
Dec 01, 2025
Non-Final Rejection — §103, §112
Feb 19, 2026
Interview Requested
Mar 18, 2026
Examiner Interview Summary
Mar 18, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12527886
RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING
2y 5m to grant Granted Jan 20, 2026
Patent 12514799
CHEMICAL MEMBRANE COMPLEX REPAIR SOLUTION AND METHOD OF USING THE SAME
2y 5m to grant Granted Jan 06, 2026
Patent 12514903
Oral Composition and Methods
2y 5m to grant Granted Jan 06, 2026
Patent 12458732
POROUS COMPOSITES WITH HIGH-ASPECT RATIO CRYSTALS
2y 5m to grant Granted Nov 04, 2025
Patent 12453624
Polymer-Free Drug Eluting Vascular Stents
2y 5m to grant Granted Oct 28, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
83%
With Interview (+27.5%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 657 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month